Try our beta test site

Impact of Providing High Protein Bar to Dialysis Patients With Low Serum Albumin

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2007 by Satellite Healthcare.
Recruitment status was:  Recruiting
Information provided by:
Satellite Healthcare Identifier:
First received: January 8, 2008
Last updated: NA
Last verified: December 2007
History: No changes posted
This study is to evaluate the impact of providing high protein supplementation in the form of a medical food bar containing 20grams of protein eath to hypoalbuminemic dialysis patients.

Condition Intervention
End Stage Renal Disease
Dietary Supplement: Protein Food Bar Intelligent Indulgence

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Impact of Providing High Protein Bar to Dialysis Patients With Low Serum Albumin

Further study details as provided by Satellite Healthcare:

Primary Outcome Measures:
  • The mean change (from baseline to month 3) in serum albumin levels among study groups and the proportion of patients treated with the protein food bar reaching an increase of 0.3 g/dL over the three month study period. [ Time Frame: Each month for the three months. ]
  • Incidence of potential adverse events including nausea, vomiting, diarrhea, acidosis, and uremic symptoms as evidenced by clinical symptoms and possible worsening of laboratory measures such as BUN, Kt/V, nPNA and bicarbonate. [ Time Frame: Each month for 3 months ]

Secondary Outcome Measures:
  • Proportion of patients who reached the goal albumin of >3.5 g/dL during the study period [ Time Frame: Month 3 ]
  • Overall acceptance and compliance of bar form medical food over a 3 month period will be assessed via the proportion of patients who ingested 75% or more of the recommended bars. [ Time Frame: Each month for 3 months ]
  • Impact of protein intake on laboratory measures such as pre-albumin, CRP and ferritin will be monitored [ Time Frame: Each month for 3 months ]

Estimated Enrollment: 375
Study Start Date: December 2007
Estimated Study Completion Date: December 2009
Estimated Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Group A
Center Hemodialysis patients
Dietary Supplement: Protein Food Bar Intelligent Indulgence
Patients will be given one protein bar at each dialysis treatment, 3 times per week for 3 months
Active Comparator: Group B
Center hemodialysis patients
Dietary Supplement: Protein Food Bar Intelligent Indulgence
Patients will be given 7 bars per week. In addition to the the three bars given on Hemodialysis each week, the patients will be given on the first treatment of the week four protein bars to be eaten on non-dialysis days
No Intervention: Group C
Center Hemodialysis Patients
Active Comparator: Group D
Peritoneal dialysis patients
Dietary Supplement: Protein Food Bar Intelligent Indulgence
Patients will be given a monthly supply of protein bars to provide for daily intake of one protein bar.
No Intervention: Group E
Peritoneal dialysis patients


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects with ESRD undergoing center hemodialysis or peritoneal dialysis for more than 90 days.
  • 18 years of age or older.
  • Must have a reasonable expectation of remaining on treatment for at least 3 months.
  • Must have an average serum albumin of <3.5 g/dL over the three months prior to entry into the study.
  • Must be able to understand and sign the informed consent.
  • Must be willing and able to participate in nutrition interviews for determination of nutrient intake from conventional foods.

Exclusion Criteria:

  • Allergy to protein, milk, nuts or wheat.
  • Documented ongoing acute infection or inflammatory process including treatment with antibiotics within a two week time of study entry.
  • Severe acidosis defined as pre-dialysis serum bicarbonate levels of <15 mEq/L.
  • Presence of conditions that would affect normal response to repletion of protein and calories, such as gastrointestinal disorders including inflammatory bowel disease.
  • Hospitalization for an infectious condition within 4 weeks prior to study entry.
  • Planned surgery within the three month study period including planned kidney transplantation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00597025

United States, California
Satellite Healthcare, Inc.
Mountain View, California, United States, 94041
WellBound, Inc.
Mountain View, California, United States, 94041
Sponsors and Collaborators
Satellite Healthcare
Principal Investigator: Brigitte Schiller-Moran, MD Satellite Healthcare, Inc.
  More Information

Responsible Party: Brigitte Schiller-Moran, Satellite Healthcare, Inc. Identifier: NCT00597025     History of Changes
Other Study ID Numbers: SR017PB 
Study First Received: January 8, 2008
Last Updated: January 8, 2008

Keywords provided by Satellite Healthcare:
Dietary Supplements
Peritoneal Dialysis

Additional relevant MeSH terms:
Kidney Failure, Chronic
Nutrition Disorders
Renal Insufficiency, Chronic
Renal Insufficiency
Kidney Diseases
Urologic Diseases
Blood Protein Disorders
Hematologic Diseases processed this record on February 20, 2017